Past-Chair of the Generic industry NHS/DH partnership group. Engaging with industry and NHS/DH colleagues in central, secondary care and CCG/CSU sectors. Working to highlight and deliver innovative and cost efficient patient care with generic medicines, supporting the medicines optimisation agenda, the findings of the carter review as well as Qipp etc. Supporting the messages of incremental innovation, revised pathways of care and better use of many generic gold standard established therapies… Show more Past-Chair of the Generic industry NHS/DH partnership group. Engaging with industry and NHS/DH colleagues in central, secondary care and CCG/CSU sectors. Working to highlight and deliver innovative and cost efficient patient care with generic medicines, supporting the medicines optimisation agenda, the findings of the carter review as well as Qipp etc. Supporting the messages of incremental innovation, revised pathways of care and better use of many generic gold standard established therapies. Our ultimate goal being enhanced concordance and compliance, optimised outcomes for patients, improved economics for the NHS and its stakeholders providing headroom for delivering world class services and best possible therapy. Show less